Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Anti-CD19-CD20 CAR T cells |
| Synonyms | |
| Therapy Description |
Anti-CD19-CD20 CAR T-cells are T-cells that are engineered to express a bispecific antibody that targets CD19 and CD20, which potentially results in an anti-tumor immune response against cells expressing either CD19 or CD20 (PMID: 27059623, PMID: 29207878). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Anti-CD19-CD20 CAR T cells | CD19 Immune Cell Therapy 72 CD20 Immune Cell Therapy 14 | Anti-CD19-CD20 CAR T-cells are T-cells that are engineered to express a bispecific antibody that targets CD19 and CD20, which potentially results in an anti-tumor immune response against cells expressing either CD19 or CD20 (PMID: 27059623, PMID: 29207878). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07166549 | Phase I | Anti-CD19-CD20 CAR T cells | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) (BaseCAR-01) | Not yet recruiting | CHE | 0 |
| NCT04049383 | Phase I | Anti-CD19-CD20 CAR T cells | CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T) | Suspended | USA | 0 |
| NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Terminated | USA | 0 |
| NCT05797233 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | Active, not recruiting | USA | 0 |